Venture Capital

As AI-driven fakes flood the world, a new asset class is born: authenticity. Discover how GME and Reality Defender are monetizing trust for government.

Beyond the hype, one company's dual leadership award reveals the true engine of the GenAI revolution: a smarter, more powerful search foundation.

Bill Ackman's fund posted a stellar 24.1% return. We dive into the high-conviction plays and innovative structure driving this market-beating performance.

With FDA approval and $80M in funding, ProVerum’s ProVee system aims to disrupt the BPH treatment market by prioritizing safety and patient quality of life.

A new partnership uses AI to analyze imaging, clinical, and molecular data, offering unprecedented accuracy in predicting breast cancer recurrence years later.

Serina Therapeutics has answered the FDA's challenge. A 30-day clock now ticks on its novel Parkinson's therapy and its disruptive drug delivery platform.

Early trial data suggests GRI-0621 could be a game-changer for Idiopathic Pulmonary Fibrosis, showing lung repair and a much better safety profile.

BridgeBio Oncology's new drug candidate BBO-10203 could redefine cancer therapy by avoiding a key toxicity, unlocking a vast market.

Aardvark Therapeutics' pivotal trial for Prader-Willi syndrome goes global, a key step toward commercializing its novel hunger-suppressing drug.

The eyewear giant is moving beyond frames, partnering to design custom chips. A strategic pivot to open-source hardware aims to redefine the market.

With Sir Nick Clegg and AI pioneer Yann LeCun on board, HIRO Capital's new fund is a bold bet on Europe's ability to lead in deep tech innovation.

A V2G pioneer pivots its intelligent software to compete for a massive national energy storage contract in South Korea's booming, high-stakes market.

The 2025 proxy season saw record director support as investors prioritized financials, yet dissent over executive pay signals a new battleground.

With a new patent, this biotech targets the massive orthopedics market. But can its novel fibroblast therapy overcome steep financial and clinical hurdles?

A showcase in LA reveals Hollywood's strategy to tap Korean creative power, with new IPs like 'Oh My Ghost Clients' poised for a global breakthrough.

Daré Bioscience is targeting a 20M-woman market with a novel arousal cream. This is the story of its clever regulatory strategy and high-stakes bet.

USA Rare Earth is accelerating its timeline to mine critical minerals by two years. Can innovative tech and bold strategy break foreign supply chain dominance?

Beyond webinars, ON24's G2 win and LinkedIn pact reveal a strategic shift to AI-driven data and connected campaigns in the B2B marketing tech war.

With a key FAA filing, Electra's hybrid-electric EL9 moves closer to reality, promising to bypass airports with 150-foot takeoffs and landings.

The space firm secures vital cash through a complex warrant deal, but at what cost to shareholders? All eyes are now on a critical investor vote.